Alzheimer’s Disease Prevention Clinical Trials: Taking the Next Steps Responsibly

Joshua Grill

University of California, Irvine
Disclosures

• Site investigator for clinical trials sponsored by Avanir, Biogen Idec, Eli Lilly, Genentech, Janssen Alzheimer Immunotherapy, and the Alzheimer’s Disease Cooperative Study (ADCS).

• Travel provided by Takeda Pharmaceuticals and Zinfandel Pharmaceuticals
Agenda

• Under what conditions is it acceptable to inform AD genetic/biomarker status?
• What are the ethical concerns for AD prevention trials?
• What data can instruct ethical AD prevention trial design and conduct?
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neumann et al.</td>
<td>General population survey</td>
<td>85% of those 60 or older would take a predictive blood test for AD. 48% for partially predictive.</td>
</tr>
<tr>
<td>Cutler and Hodgson</td>
<td>108 adult children age 40-60 and a matched sample with no family hx</td>
<td>68% of adult children and 62% of controls (NS) were likely to take a 100% accurate predictive blood test</td>
</tr>
<tr>
<td>Neumann et al.</td>
<td>1463 US respondents (mean age=43)</td>
<td>&gt;70% would take predictive AD blood test, even if imperfect</td>
</tr>
<tr>
<td>Wikler et al.</td>
<td>2678 US and European adults (82% &lt;65)</td>
<td>67% were somewhat or very likely to get an early medical test</td>
</tr>
<tr>
<td>Roberts et al.</td>
<td>Health and Retirement Survey (mean age 64)</td>
<td>60% somewhat or strongly agreed that they wished to know their AD risk</td>
</tr>
<tr>
<td>Caselli et al.</td>
<td>Alzheimer’s Prevention Initiative registrants</td>
<td>81% wanted genetic testing if it were paid for by insurance, 59% willing to pay. 80% wanted biomarker testing.</td>
</tr>
</tbody>
</table>

Predicting AD Dementia

HR (95% CI)

- APOE ε4: OR=0.98, CI: 0.20-4.90, p=0.98
- Age: OR=1.14, CI: 1.02-1.28, p=0.03
- Elevated amyloid: OR=4.85, CI: 1.22-19.01, p=0.02

Appropriate Use Criteria for Clinical Amyloid Imaging

**Appropriate**

1. Persistent or progressive unexplained MCI
2. Possible AD because of unclear clinical presentation, either an atypical clinical course or an etiologically mixed presentation
3. Atypical early age of onset (usually defined as 65 years or less in age)

**Inappropriate**

1. Patients with core clinical criteria for probable AD with typical age of onset
2. To determine dementia severity
3. Based solely on a positive family history of dementia or presence of apolipoprotein E (APOE)ε4
4. Patients with a cognitive complaint that is unconfirmed on clinical examination
5. In lieu of genotyping for suspected autosomal mutation carriers
6. In asymptomatic individuals
7. Nonmedical use (e.g., legal, insurance coverage, or employment screening)

## On-Going Preclinical AD Trials

<table>
<thead>
<tr>
<th>Trial/Organizing Group</th>
<th>Treatment</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Amyloid treatment in Asymptomatic AD / ADCS</td>
<td>Solanezumab</td>
<td>Preclinical sporadic AD (elevated brain amyloid PET signal with normal cognition)</td>
</tr>
<tr>
<td>AD Prevention through Exercise</td>
<td>Exercise</td>
<td>Preclinical sporadic AD</td>
</tr>
<tr>
<td>Crenezumab in PSEN1 E280 Mutation carriers</td>
<td>Crenezumab (subcutaneous)</td>
<td>PSEN1 mutation carriers and non-carriers</td>
</tr>
<tr>
<td>DIAN TU. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation</td>
<td>Gantenerumab and Solanezumab</td>
<td>Asymptomatic and mildly symptomatic carriers and non-carriers of ADAD mutations</td>
</tr>
<tr>
<td>Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)</td>
<td>Pioglitazone</td>
<td>Biomarker risk algorithm (BRAA) composed of TOMM40 rs10524523 genotype, APOE genotype, and age</td>
</tr>
<tr>
<td>Alzheimer's Prevention Initiative APOE4 Treatment Trial</td>
<td>CAD-106, BACE inhibitor</td>
<td>APOE e4 homozygotes</td>
</tr>
</tbody>
</table>

Trial Designs in Preclinical AD

1. Blinded enrollment – a proportion of participants who do not meet biomarker or genetic criteria are enrolled so that enrollment is not *de facto* disclosure of biomarker status. Those participants are non-randomly assigned to placebo and complete the entire protocol.

2. Transparent enrollment – only participants meeting biomarker or genetic criteria are enrolled and randomized to drug or placebo.
Criteria for Ethical Research

- Social value
- Informed consent
- Fair selection of subjects
- Favorable risk-benefit ratio
- Independent review
- Respect for enrolled subjects
- Scientific validity

Special Issues in Preclinical AD Trial Informed Consent

Blinded Designs
- Procedural risks (blood draws, neuroimaging, lumbar puncture) without potential benefit
- Unwanted disclosure of risk status, e.g., adverse events

Transparent Designs
- Risk of learning risk status but not receiving effective therapy or even qualifying for the trial
- Unknown what proportion become impaired or what timeline will impairment occur?
Is the Requirement of Disclosure Coercion?

- Coercion: overt threat of harm to elicit compliance
- Undue influence: improper or inappropriate reward to elicit compliance
- Transparent enrollment is neither coercive nor does it offer undue influence
- Informed consent is critical to respect the autonomy of participants

To Be Ethical, Prevention Trials Must Be Feasible

• “...If persons who at baseline wish not to know their mutation status choose not to participate, then a majority of persons at risk for the condition would be excluded.”

Kim et al. Neurology 2015
Do you currently know if you are a carrier of a gene mutation that causes familial AD?

A1. Would you be interested in participating in a research study of an experimental drug to determine if that drug does (or does not) prevent or slow the development of familial AD?

   - Yes
   - No

   No
   - Check the reasons that apply
     - I don't carry mutation
     - I would not risk side effects
     - Too much time and effort
     - Other
   - Stop here.

A2. Would your opinion about such studies change if, instead of knowing for sure that you would receive the real drug, you had a 50% chance of receiving the real drug and 50% chance of receiving placebo?

   - Yes
   - No

   Yes
   - Check the reasons that apply
     - I don't want to keep if I will get AD
     - I do not want to participate in a study of an unproven drug
     - I would not risk side effects
     - Too much time and effort
     - Other
   - Stop here.

A3. Would your opinion about such studies change if, instead of knowing for sure that you would receive the real drug, you had two chances of receiving the real drug and one chance of receiving placebo (that is, 2/3 of subjects receive the real drug and 1/3 receive a placebo)?

   - Yes
   - No

   Yes
   - Check the reasons that apply
     - I don't want to know if I will get AD
     - I do not want to participate in a study of an unproven drug
     - I would not risk side effects
     - Too much time and effort
     - Other
   - Stop here.

B1. Would you change your mind if learning that you carried the gene mutation that causes familial AD gave you the opportunity to participate in a research study of an experimental drug to determine if that drug does (or does not) prevent or slow the development of familial AD?

   - Yes
   - No

   No
   - Check the reasons that apply
     - I don't carry mutation
     - I would not risk side effects
     - Too much time and effort
     - Other
   - Stop here.

B2. Would your opinion about such studies change if, instead of knowing for sure that you would receive the real drug, you had a 50% chance of receiving the real drug and 50% chance of receiving placebo?

   - Yes
   - No

B3. Would your opinion about such studies change if, instead of knowing for sure that you would receive the real drug, you had two chances of receiving the real drug and one chance of receiving placebo (that is, 2/3 of subjects receive the real drug and 1/3 receive a placebo)?

   - Yes
   - No

B4. Should you receive placebo during the study and there was the possibility of receiving active drug after the study was completed, would you now be interested in participating?
Genetic Testing in Autosomal Dominant AD Trials

- Already know status (40%)
- Wish to know status (15%)
- Do not know status (45%)
- Willing to participate (86%)
- Willing to find out to be in a trial (72%)

N=80 respondents from DIAN longitudinal study

A Randomized Study to Examine Recruitment in Transparent Enrollment Preclinical AD Trials

Randomization

132 65+ year old community volunteers recruited primarily through community outreach

Randomization

Transparent Design Preclinical AD trial

Willingness to Participate

Blinded Design Preclinical AD trial

Willingness to Participate

Grill et al. under review.
Transparent and Blinded Enrollment Rates Do Not Differ

Willingness to Enroll

Grill et al. under review.

Effect of group assignment; OR=1.30; 95% CI:0.71-2.38.
# Amyloid Imaging Disclosure Process

## Round 1:
Experts reviewed a slideshow presentation on PET amyloid imaging and its role in trials such as A4, and then completed telephone interviews designed to elicit amyloid imaging disclosure best practices and discussion topics. Transcribed responses were grouped and standardized for language consistency.

## Round 2:
Experts rated the necessity of each Round 1 item (include, unsure, do not include) through an online survey. Responses were compiled and items were categorized into three levels of support:

- **Consensus to include** (support of ≥ 8 experts)
- **Mixed support** (support of 5-7 experts)
- **Do not include** (support of < 5 experts)

Mixed support items were included if the majority of remaining votes were “unsure” rather than “do not include.” Items with consensus support were included in a template brochure and disclosure process guidelines.

## Round 3:
Experts rated brochure sections for clarity (5 point scale) and provided comments through an online survey. We used comments for revisions, with attention to mean clarity ratings lower than 4.
Amyloid Imaging Disclosure Recommendations

- A pre-consent education: verbal and written information covering what is and is not known about amyloid imaging, possible imaging results and their meaning, implications of results, and information about Alzheimer’s disease and risk factors
- The person conducting the educational session should assess comprehension, specifically how well the individual understands amyloid imaging and its role in the study
- Participants should be queried about motivation for joining the study and willingness to learn amyloid status
- Participants should be screened for anxiety and depression
- The person conducting the educational and disclosure sessions should be skilled in communication and recognizing distress

Amyloid Imaging Disclosure Recommendations

- Imaging should occur on a separate day from consent and disclosure on a separate day from imaging.
- At disclosure, investigators should first assess mood and willingness to receive results, and should provide a written report of results.
- Disclosure should occur in person, with time for questions.
- Telephone follow-up should occur within a few days of disclosure to assess participant mood and impact of disclosure.
- Participants showing distress should receive additional monitoring and follow-up.
- Periodic assessment of depression and anxiety should be scheduled following disclosure.

A4 Data Collection

Follow-up over the course of the study

- **Geriatric Depression Scale** (GDS), the **State Trait Anxiety Inventory** (STAI), and the **Columbia suicide severity rating scale** (C-SSRS) are administered at 3-6 month intervals

- Assessments of participant’s understanding of amyloid status disclosure and concerns about AD
  - Perceived risk of AD dementia
  - Future Time Perspective
  - Reasons to undergo amyloid imaging
Anxiety and Cognitive Decline in Preclinical AD

Figure 1. Slopes of Change in Verbal Memory Composite Score by Amyloid-β (Aβ) and Anxiety Levels

Slopes are adjusted for age, educational level, full-scale IQ, APOE genotype, subjective memory complaints, number of vascular risk factors, and depressive symptoms.

Figure 2. Slopes of Change in Language Composite Score by Amyloid-β (Aβ) and Anxiety Levels

Slopes are adjusted for age, educational level, full-scale IQ, APOE genotype, subjective memory complaints, number of vascular risk factors, and depressive symptoms.

Pietrzak et al. JAMA Psychiatry 2015.
## Considering Suicide in Prevention Trials

<table>
<thead>
<tr>
<th>Activity</th>
<th>Genetic evidence of increased AD risk</th>
<th>Biomarker evidence of increased AD risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Begin a healthier lifestyle</td>
<td>90.5 (3478/3841)</td>
<td>91.0 (3459/3798)</td>
</tr>
<tr>
<td>Get long-term care insurance</td>
<td>76.3 (2819/3693)</td>
<td>76.6 (2783/3634)</td>
</tr>
<tr>
<td>Spend all your money for pleasure</td>
<td>18.4 (683/3720)</td>
<td>18.7 (682/3656)</td>
</tr>
<tr>
<td>Seriously consider suicide</td>
<td>11.6 (427/3706)</td>
<td>10.2 (370/3639)</td>
</tr>
</tbody>
</table>

Considering Suicide in Prevention Trials

• At least some participants (and researchers) endorse risk information as a means to instruct planned suicide
  – To ensure the social value of the study (and future such studies) risk of suicide occurrence must be minimized.
• Long-term follow-up, even after study completion, perhaps especially in the setting of negative results, will be required
• The disclosure of risk information in the controlled, protocol-derived setting, with participants meeting pre-specified criteria, may not generalize to clinical care
Risk Factors for Suicide in AD

<table>
<thead>
<tr>
<th>Risk Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
</tr>
<tr>
<td>Mild disease</td>
</tr>
<tr>
<td>High education</td>
</tr>
<tr>
<td>Insight into impairment</td>
</tr>
<tr>
<td>History of depression</td>
</tr>
<tr>
<td>Access to firearms</td>
</tr>
</tbody>
</table>

Risk Factors for Suicide in Predictive Testing for AD

Not currently married

Employment and Insurance

• Issues in employment and insurance
  – EMR mixes clinical and research data
  – AE’s generate a record

• Possible protections
  – Genetic Information Nondiscrimination Act
  – HIPAA
  – Americans with Disabilities Act

• These issues need to be in the IC form

Confidentiality in Preclinical AD trials

• Potential breaches
  – Neuroimaging that is incorporated to the EMR
  – Adverse events that lead to ED visits incorporated to the EMR

• Protections/Solutions
  – “sensitive orders”
  – Research Record Numbers (vs Medical Record Numbers)
  – Information redaction (consider data trails)

Stigma in Preclinical AD

- Family and friends
- Employers
- Health care providers
- Self-stigma?

Impact of Knowing

• Does telling an older adult he or she has elevated brain amyloid change subjective memory self-efficacy?

Capacity Scale of the Metamemory in Adulthood Questionnaire

Logical Memory Test, Delayed Recall

Significant genotype-by-disclosure status interaction effect (F=9.3, df=1, 137, p<0.01)

t=4.11, df=44, p<0.001

Ethical Concerns if Trials Demonstrate Efficacy

1. The cost of diagnostic tests to screen for responders (e.g., amyloid PET scan or ApoE genotyping),
2. Refusal of treatment to persons who do not fit the responder profile (wrong genotype, too old, dementia stage too severe),
3. Access and cost of treatment (e.g., monthly intravenous infusions or injections)
4. Safety monitoring for brain edema and microhemorrhages using serial MRI
5. When to stop treatment

Summary

• Requiring disclosure of eligibility for preclinical AD trials is not unethical
• To be ethical, transparent enrollment trials must be feasible
  – Preliminary results suggest that these designs may be feasible in sporadic and even autosomal dominant preclinical AD
• Research is needed to better understand whether learning preclinical AD status
  – Is an incentive to enroll in sporadic AD trials
  – Alters the decision-making calculus in autosomal dominant AD trials or if therapeutic misconception could occur
  – Results in stigma or stereotype threat
Acknowledgements

Preclinical AD barriers study
• Jason Karlawish, MD
• Yan Zhou, PhD
• David Elashoff, PhD

DIAN survey study
• Randy Bateman, MD
• Virginia Buckles, PhD
• Angela Oliver
• Colin Masters, MD
• William Klunk, MD, PhD
• John Morris, MD
• John Ringman, MD, MS

A4 Internal Ethics Committee
• Jason Karlawish, MD
• Jeffrey Burns, MD
• David Sultzer, MD
• Reisa Sperling, MD (PI)

Funding
• Alzheimer’s Association NIRG 12-242511
• NIH AG016573
• DIAN and DIAN TU: NIH U01AG042791, U01AG042791-S1, R01AG046179
• AD Cooperative Study NIH AG010483